Advancing precision and personalized breast cancer treatment through multi-omics technologies

Area of Science:

• Oncology
• Genomics
• Proteomics
• Transcriptomics
• Personalised Medicine

Background:

• Breast cancer is a leading cause of cancer death in women, with heterogeneity complicating diagnosis and treatment.
• Traditional diagnostic methods are insufficient for precise characterisation.
• Advances in multi-omics offer deeper insights into breast cancer biology.

Purpose of the Study:

• To review recent advances in molecular subtyping and multi-omics technologies for breast cancer.
• To highlight innovations driving optimised patient outcomes and personalised medicine.
• To underscore the importance of integrating multi-omics with conventional diagnostics.

Main Methods:

• Genomic, proteomic, and transcriptomic analyses to understand breast cancer heterogeneity.
• Integration of multi-omics data with conventional diagnostic methods.
• Utilisation of liquid biopsy and artificial intelligence for enhanced tumour follow-up and data analysis.

Main Results:

• Multi-omics enables precise molecular subtyping, identifying key mutations and gene expression patterns.
• Integration improves tumour characterisation and prognostic accuracy.
• New therapeutic targets and gene expression dynamics are elucidated.

Conclusions:

• Multi-omics approaches, combined with clinical phenotyping, hold significant potential for precision breast cancer treatment.
• These technologies are crucial for developing personalised medicine strategies.
• Continued innovation is key to optimising patient outcomes in breast cancer care.